AP-004

Myeloma, 65 to 74, suburban, Medicare Advantage

CAR-T · Phase 2, Candidacy Evaluation · 14 days in stage · 5 barriers, 2 blocking

On track

Follow one barrier

Diagnosis & Referral

From diagnosis to first contact with an accredited center.

Any order, all required

Start ahead · work beginning here for later phases

Plan bridging early with a standardized protocol; avoid bendamustine before apheresis · Manufacturing / collection & vein-to-vein risk · for phase 4
Enroll in manufacturer assistance / copay programs · Financial toxicity / out-of-pocket burden · for phase 2

The work-up that determines whether the center will proceed. Most tests run in parallel and all feed the selection decision.

Any order, all required

Start ahead · work beginning here for later phases

Verify benefits and secure prior authorization before apheresis · Insurance coverage & prior-authorization · for phase 3
Ask about early leukapheresis + cryopreservation to protect T-cell fitness · Manufacturing / collection & vein-to-vein risk · for phase 4

Securing payer approval and financial clearance for the specific therapy.

Any order, all required

Obtaining the cells and getting the patient ready. This is where CAR-T and allogeneic transplant diverge.

CAR-T track

Shared preparation — in parallel with collection

Any order, all required

Conditioning, infusion, and the acute monitoring window.

Monitoring, transition back home, and long-term survivorship.